Dr Michael Thurn, Managing Director and CEO, commented: "The FDA’s clearance of our IND application marks a significant milestone in our mission to bring NUZ-001 closer to patients living with ALS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback